Predictors of Regulatory Approval Success for Generic Pharmaceutical Products in Nigeria: A Survival Analysis of NAFDAC Dossier Submissions Over a Decade

Generic medicine registration is a critical pathway through which affordable, quality-assured medicines reach Nigerian patients. However, high rates of regulatory dossier rejection by the National Agency for Food and Drug Administration and Control impose substantial delays and costs on pharmaceutical manufacturers. The predictors of successful first-cycle approval have not been systematically studied using rigorous analytical methods. This study identified predictors of regulatory approval success for generic pharmaceutical product submissions at NAFDAC over a ten-year period using survival analysis methodology. A retrospective cohort of 1,120 generic product dossiers submitted between 2014 and 2023 was constructed from NAFDAC archival records. Time-to-approval was defined as the primary outcome, and regulatory survival was analyzed using Kaplan-Meier methods and Cox proportional hazard regression. Predictor variables included dosage form, therapeutic category, applicant company type, country of origin of active pharmaceutical ingredients, dossier format, and prior NAFDAC consultation history. Median time to approval was 28.4 months. First-cycle approval was achieved in 38 percent of submissions. Cox regression identified Common Technical Document-formatted dossiers, prior pre-submission meetings with NAFDAC, solid oral dosage forms, and active pharmaceutical ingredients from pre-qualified sources as significant predictors of faster and more successful approval. Injectables and biologics had the longest approval timelines. The study provides the first empirical survival analysis of NAFDAC regulatory performance and offers actionable guidance for pharmaceutical companies optimizing dossier submissions. Keywords: regulatory approval, generic medicines, NAFDAC, survival analysis, pharmaceutical registration